Skip to main content
. 2021 Sep 17;12:714138. doi: 10.3389/fimmu.2021.714138

Figure 2.

Figure 2

Formyl peptide receptor (FPR) blockade impairs clinical and histological improvements induced by infliximab (IFX) during colitis. (A) Loss of body weight. (B) Disease Activity Index (DAI). (C) Area under the curve from DAI, early and late phases. (D, E) Colon length and anatomic changes. (F) Colonic MMP-9 levels. Mean of all samples (continuous lines). Bar, 1 cm. aa p < 0.01 (DSS vs. Control); b p < 0.05 (DSS+IFX vs. DSS); c p < 0.05 (DSS+Boc-2 vs. DSS); d p < 0.05 (DSS+IFX+Boc-2 vs. DSS); e p < 0.05, ee p < 0.01, eee p < 0.001 (DSS+IFX+Boc-2 vs. DSS+IFX). *p < 0.05, **p < 0.01, ***p < 0.001. n = 4–6 mice/group. Results are expressed as the mean ± SEM. (G–K) Histopathology in wild-type (WT) groups. Ulcer (black arrows), altered crypts (white arrows), crypt abscesses (white arrowheads), edema (Ed), and inflammatory infiltrate (circles). Staining, hematoxylin–eosin; embedding, paraffin; sections, 3 μm. Bars, 20 μm.